Efficacy and safety of mesenchymal stem cell therapy in acute on chronic liver failure: a systematic review and meta-analysis of randomized controlled clinical trials

Stem Cell Research & Therapy, Journal Year: 2025, Volume and Issue: 16(1)

Published: April 20, 2025

Acute-on-chronic liver failure has become a serious global health burden, which is characterized by an acute deterioration of function, rapidly evolving organ failure, and high short-term mortality in patients with chronic disease. The pathogenesis includes extensive hepatic necrosis, related to intense systemic inflammation subsequently causes the inflammatory cytokine storm, resulting portal hypertension, dysfunction, failure. Mesenchymal stem cells can function as seed remodel repair damaged tissues, thus showing potential therapeutic alternatives for However, standard treatment protocols mesenchymal acute-on-chronic have not been established. We conducted detailed search from PubMed/Medline, Web Science, EMBASE, Cochrane Library find randomized controlled trials published before October 23, 2021. formulated criteria literature screening according PICOS principle (Population, Intervention, Comparison, Outcome, Study design). Subsequently, bias risk assessment tool was used assess quality all enrolled studies. Finally, outcome measurements including model end-stage disease score, albumin, total bilirubin, coagulation aminotransferase were extracted statistical analysis. A 7 clinical included. results studies indicated that who received inoculation showed decreased MELD score 4 weeks 24 weeks, compared counterparts conventional treatment. Reciprocally, improved ALB levels weeks. For secondary indicators, significantly reduced INR ALT levels, control group. Our no significant differences incidence adverse reactions or events monitored after inoculation. This meta-analysis cell infusion effective safe Without increasing events, MSC decrease increase large-cohort longer follow-up periods are required further confirm our conclusions.

Language: Английский

Implantation of porcine amniotic epithelial cells model for myocardial infarction combined with cardiomyocyte therapy of pigs (

PubMed, Journal Year: 2025, Volume and Issue: 15(1), P. 98 - 107

Published: Jan. 1, 2025

Myocardial infarction (MI) is the most common heart disorder in patients with cardiovascular disease. Obstruction of blood flow to causes ischemia and results pump failure. This study aims evaluate effects porcine amniotic epithelial cell (pAEC)-based stem therapy alone combination cardiomyocytes understand its potential benefits MI treatment. In this study, we conducted using pluripotent cells derived from amnion (AEC) implanted into infarcted heart. Nine domestic pigs (Sus scrofa domestica), aged 3-4 months weighing 35-40 kg, were used as models. The animal models divided three groups: placebo group, group treated pAEC cells, combined cardiomyocyte cells. Electrocardiography (ECG), pulsed wave (PW) Doppler, biomarker examinations performed intervention on MI. Single lesions demonstrated improvements VTI, particularly renal artery, mitral, tricuspid valve compared untreated (placebo). Notably, single significantly improved more than combining them cardiomyocytes. Treatment AEC resulted significant function large vessels allowed us better hemodynamics parameters injury.

Language: Английский